Issue 3/2017
Content (16 Articles)
The oncology day hospital in Spain: an updated analysis of Spanish Society of Medical Oncology (SEOM) looking forward
C. Jara, F. Ayala, J. A. Virizuela
Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
A. Lester, R. Rapkins, S. Nixdorf, M. Khasraw, K. McDonald
Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI)
J. Capdevila, J. C. Galofré, E. Grande, C. Zafón Llopis, T. Ramón y Cajal Asensio, E. Navarro González, P. Jiménez-Fonseca, J. Santamaría Sandi, J. M. Gómez Sáez, G. Riesco Eizaguirre
European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish
V. Guillem, C. Camps, A. Carrato, E. Díaz-Rubio, P. Gascón
New clinical trials regulation in Spain: analysis of royal decree 1090/2015
M. Martin Jimenez, A. Calvo Ferrandiz, J. Aparicio Urtasun, R. Garcia-Campelo, E. Gonzalez-Flores, M. Lazaro Quintela, M. Muñoz Mateu, C. A. Rodriguez Sanchez, A. Santaballa Bertran, J. M. Sepulveda Sanchez, R. Vera Garcia, J. A. Virizuela Echaburu, M. A. Segui Palmer
Incidence and survival time trends for Spanish children and adolescents with leukaemia from 1983 to 2007
R. Marcos-Gragera, J. Galceran, C. Martos, A. L. de Munain, M. Vicente-Raneda, C. Navarro, J. R. Quirós-Garcia, M.-J. Sánchez, E. Ardanaz, M. Ramos, A. Mateos, D. Salmerón, S. Felipe, R. Peris-Bonet
Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG)
N. Kentepozidis, P. Economopoulou, Ch. Christofyllakis, L. Chelis, A. Polyzos, N. Vardakis, F. Koinis, L. Vamvakas, P. Katsaounis, K. Kalbakis, Ch. Nikolaou, V. Georgoulias, A. Kotsakis
M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC
T. Chu, L. Jiang, W. Ying, B. Han
Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs
S. Chen, J. Zhao, L. Cui, Y. Liu
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions
J. Salvador, J. A. Urtasun, F. J. B. Duart, R. García-Campelo, R. G. Carbonero, P. Lianes, A. Llombart, D. I. Casado, J. M. Piera, M. M. Mateu, J. Puente, F. Rivera, C. A. Rodríguez, J. A. Virizuela, M. Martín, P. Garrido
Clinical behavior of solitary fibrous tumor: a retrospective review of 30 patients
Mª A. Vaz Salgado, M. Soto, Mª E. Reguero, G. Muñoz, A. Cabañero, I. Gallego, S. Resano, F. Longo, A. Madariaga, A. Gomez, A. Carrato
Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib
A. Lamarca, O. Abdel-Rahman, I. Salu, M. G. McNamara, J. W. Valle, R. A. Hubner
Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study
F. Casas, I. Henríquez, A. Bejar, X. Maldonado, A. Alvarez, C. González-Sansegundo, A. Boladeras, F. Ferrer, A. Hervás, I. Herruzo, M. Caro, I. Rodriguez, C. Ferrer
Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery
J. Arredondo, J. Baixauli, C. Pastor, A. Chopitea, J. J. Sola, I. González, J. A-Cienfuegos, P. Martínez, J. Rodriguez, J. L. Hernández-Lizoain
Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors
A. Carmona-Bayonas, P. Jiménez-Fonseca, J. Virizuela, M. Antonio, C. Font, M. Biosca, A. Ramchandani, J. Martinez-Garcia, J. Hernando, J. Espinosa, E. M. de Castro, I. Ghanem, C. Beato, A. Blasco, M. Garrido, R. Mondéjar, M. Á. Arcusa, I. Aragón, A. Manzano, E. Sevillano, E. Castañón, F. Ayala